Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer
复制标题
III 类 β-微管蛋白表达对于选择白蛋白结合型紫杉醇和吉西他滨作为不可切除胰腺癌的一线治疗具有价值
DOI：
10.1097/mpa.0000000000002032
复制
发表时间：
2022
期刊：
影响因子：
2.9
通讯作者：
Kataoka H.
中科院分区：
文献类型：
--
作者：
Kato A;Naitoh I;Naiki-Ito A;Hayashi K;Okumura F;Fujita Y;Sano H;Nishi Y;Miyabe K;Inoue T;Hirano A;Takada H;Yoshida M;Hori Y;Natsume M;Kato H;Takahashi S;Kataoka H.
目的：Nab-紫杉醇联合吉西他滨(GNP)或FOLFIRINOX(亚叶酸钙、氟尿嘧啶、伊立替康和奥沙利铂[FFX]的组合)目前被认为是治疗不能切除的胰腺导管腺癌(PDAC)的标准一线方案。III型β-微管蛋白(TUBB3)有可能预测多种肿瘤对紫杉烷的耐药性；我们回顾了113例接受GNP或FFX一线化疗的PDAC患者，用免疫组织化学方法检测了TUBB3的表达情况。结果TUBB3的高表达与疾病控制率(P=0.017)和无进展生存期(PFS)显著降低(P=0.019)相关，多因素分析显示TUBB3的表达是一线组PFS的独立变量(P=0.045)。此外，在FFX一线组中，TUBB3的表达与PFS或总生存期(OS)无关。结论III型β微管蛋白可作为预测GNP疗效的指标，但不能预测OS的预后，有助于选择不能手术切除的一线化疗方案。
ObjectivesNab-paclitaxel and gemcitabine (GnP) or FOLFIRINOX (a combination of leucovorin, fluorouracil, irinotecan, and oxaliplatin [FFX]) is currently recognized as the standard first-line regimen for unresectable pancreatic ductal adenocarcinoma (PDAC). Class III β-tubulin (TUBB3) has the potential to predict resistance to taxane in various tumors; therefore, this study aimed to clarify whether TUBB3 is a predictive marker for GnP response.MethodsWe retrospectively reviewed 113 patients with PDAC who received GnP or FFX as first-line chemotherapy and examined immunohistochemically the TUBB3 expression in specimens obtained by endoscopic ultrasound-guided fine-needle aspiration.ResultsHigh TUBB3 expression was associated with a significantly lower disease control rate (P= 0.017) and shorter progression-free survival (PFS)(P= 0.019), and multivariate analysis revealed that TUBB3 expression was an independent variable for PFS in the GnP first-line group (P= 0.045). In addition, in the FFX first-line group, TUBB3 expression was not correlated with PFS or overall survival (OS). In all 113 patients, TUBB3 expression was not also associated with OS.ConclusionsClass III β-tubulin might be a predictive factor for the response of GnP, but not a prognostic factor for OS, helping the selection of an optimized first-line chemotherapy regimen for unresectable PDAC.